Viewing 0 reply threads
  • Author
    • #17103

      This letter provided by FARA (Friedreich’s Ataxia Research Alliance) is addressed to FDA & Reata Pharmaceuticals to allow individuals with Friedreich’s Ataxia access to Omaveloxolone, a new clinically proven drug that slows down the progression of FA.

      This letter requests Reata to submit a New Drug Application (NDA) on an urgent basis and FDA to exercise the flexibility granted by law and contained in FDA guidance in considering approval of an NDA for Omavaloxolone in FA based on the existing evidence from clinical trials.

      The effects of this drug will help significantly slow down our progression by improving the symptoms of detexerity, walking, speech and fatigue levels improved.

      To sign, click here:

Viewing 0 reply threads
  • You must be logged in to reply to this topic.

©2022 KLEO Template a premium and multipurpose theme from Seventh Queen


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account